CAMBRIDGE, Mass. and BERLIN, Germany — Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the Company reached its initial recruitment and genetic testing milestone in the observational EFRONT Study, being conducted to advance the genetic understanding of frontotemporal dementia...
treatment News
TORONTO, Canada – CAMH-led pre-clinical studies using a small molecule drug have shown promise as a potential new treatment for multiple sclerosis (MS). The results have been published today in the journal Science Advances. Expanding on Dr. Fang Liu’s earlier work that identified a novel drug target for the treatment...
FRAZER, Pa. — Cephalon, Inc. (Nasdaq: CEPH) today announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show the benefit of lestaurtinib in this patient population when given in sequence with standard...
SUNNYVALE, Calif. — Cepheid (Nasdaq: CPHD) today announced the release of its improved Xpert(R) BCR-ABL Monitor test to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. With improved time-to-results, the test now detects the BCR-ABL chromosomal translocation in about 2 hours...
SAN DIEGO — Ceregene, Inc. today reported additional clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson’s disease. CERE-120 uses AAV-based gene therapy to deliver the neurotrophic factor, neurturin, to Parkinson’s disease patients in order to restore the function and protect degenerating...
CAMBRIDGE, Mass. — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neurological diseases, today announced positive topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon, the first and only D1/D5 receptor partial agonist being studied as a once-daily treatment for...
SOUTH SAN FRANCISCO, Calif. – Cero Therapeutics Holdings, Inc., (NASDAQ:CERO) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms today announced the publication in Clinical Cancer Research, a journal of the American Association for Cancer Research, a paper titled “Therapeutic...
MELBOURNE, Australia — Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational therapy FT011 for the treatment of systemic sclerosis (Systemic scleroderma), having previously...
DUBLIN, Ireland— The “Cervical Intraepithelial Neoplasia – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com’s offering. The “Cervical Intraepithelial Neoplasia – Pipeline Insight, 2023” report offers a comprehensive overview of the Cervical Intraepithelial Neoplasia (CIN) pipeline landscape, featuring insights into more than 8 companies and over 10 pipeline drugs....
LONDON, UK – CHARM Therapeutics (“CHARM”, “The Company”), today announced the advancement of CHM-029, a next-generation pan-menin inhibitor designed to overcome resistance mutations, as a development candidate for the treatment of acute myeloid leukemia (AML). It is expected that CHM-029 will enter first-in-human trials in Q2 2026. Menin inhibitors have emerged...